Literature DB >> 24972532

PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans.

Andreas Peter1, Marketa Kovarova, Silvio Nadalin, Tomas Cermak, Alfred Königsrainer, Fausto Machicao, Norbert Stefan, Hans-Ulrich Häring, Erwin Schleicher.   

Abstract

AIMS/HYPOTHESIS: The common sequence variant I148M of the patatin-like phospholipase domain-containing protein 3 gene (PNPLA3) is associated with increased hepatic triacylglycerol (TAG) content, but not with insulin resistance, in humans. The PNPLA3 (I148M) variant was previously reported to alter the specificity of the encoded enzyme and subsequently affect lipid composition.
METHODS: We analysed the fatty acid composition of five lipid fractions from liver tissue samples from 52 individuals, including 19 carriers of the minor PNPLA3 (I148M) variant.
RESULTS: PNPLA3 (I148M) was associated with a strong increase (1.75-fold) in liver TAGs, but with no change in other lipid fractions. PNPLA3 (I148M) minor allele carriers had an increased n-3 polyunsaturated fatty acid (PUFA) α-linolenic acid content and reductions in several n-6 PUFAs in the liver TAG fraction. Furthermore, there was a strong inverse correlation between n-6 PUFA and TAG content independent of PNPLA3 genotype. In a multivariate model including liver fat content, PNPLA3 genotype and fatty acid composition, two significant differences could be exclusively attributed to the PNPLA3 (I148M) minor allele: reduced stearic acid and increased α-linolenic acid content in the hepatic TAG fraction.
CONCLUSIONS: These changes therefore suggest a mechanism to explain the PNPLA3 (I148M)-dependent increase in liver fat content without causing insulin resistance. Stearic acid can induce insulin resistance, whereas α-linolenic acid may protect against it.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24972532     DOI: 10.1007/s00125-014-3310-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  10 in total

Review 1.  Omega 3 - Omega 6: What is right for the liver?

Authors:  Ashraf Mohammad El-Badry; Rolf Graf; Pierre-Alain Clavien
Journal:  J Hepatol       Date:  2007-09-14       Impact factor: 25.083

2.  Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.

Authors:  Y-L Liu; G L Patman; J B S Leathart; A-C Piguet; A D Burt; J-F Dufour; C P Day; A K Daly; H L Reeves; Q M Anstee
Journal:  J Hepatol       Date:  2014-03-06       Impact factor: 25.083

3.  Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis.

Authors:  John Zhong Li; Yongcheng Huang; Ruchan Karaman; Pavlina T Ivanova; H Alex Brown; Thomas Roddy; Jose Castro-Perez; Jonathan C Cohen; Helen H Hobbs
Journal:  J Clin Invest       Date:  2012-11       Impact factor: 14.808

Review 4.  Human fatty liver disease: old questions and new insights.

Authors:  Jonathan C Cohen; Jay D Horton; Helen H Hobbs
Journal:  Science       Date:  2011-06-24       Impact factor: 47.728

5.  PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis.

Authors:  Julia Perttilä; Carolina Huaman-Samanez; Sandrine Caron; Kimmo Tanhuanpää; Bart Staels; Hannele Yki-Järvinen; Vesa M Olkkonen
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-14       Impact factor: 4.310

6.  High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease.

Authors:  K Kantartzis; C Thamer; A Peter; J Machann; F Schick; C Schraml; A Königsrainer; I Königsrainer; S Kröber; A Niess; A Fritsche; H-U Häring; N Stefan
Journal:  Gut       Date:  2008-12-11       Impact factor: 23.059

7.  PNPLA3 mediates hepatocyte triacylglycerol remodeling.

Authors:  Hanna Ruhanen; Julia Perttilä; Maarit Hölttä-Vuori; You Zhou; Hannele Yki-Järvinen; Elina Ikonen; Reijo Käkelä; Vesa M Olkkonen
Journal:  J Lipid Res       Date:  2014-02-07       Impact factor: 5.922

8.  A lipidomic analysis of nonalcoholic fatty liver disease.

Authors:  Puneet Puri; Rebecca A Baillie; Michelle M Wiest; Faridoddin Mirshahi; Jayanta Choudhury; Onpan Cheung; Carol Sargeant; Melissa J Contos; Arun J Sanyal
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

9.  Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase.

Authors:  Manju Kumari; Gabriele Schoiswohl; Chandramohan Chitraju; Margret Paar; Irina Cornaciu; Ashraf Y Rangrez; Nuttaporn Wongsiriroj; Harald M Nagy; Pavlina T Ivanova; Sarah A Scott; Oskar Knittelfelder; Gerald N Rechberger; Ruth Birner-Gruenberger; Sandra Eder; H Alex Brown; Guenter Haemmerle; Monika Oberer; Achim Lass; Erin E Kershaw; Robert Zimmermann; Rudolf Zechner
Journal:  Cell Metab       Date:  2012-05-02       Impact factor: 27.287

10.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.

Authors:  Stefano Romeo; Julia Kozlitina; Chao Xing; Alexander Pertsemlidis; David Cox; Len A Pennacchio; Eric Boerwinkle; Jonathan C Cohen; Helen H Hobbs
Journal:  Nat Genet       Date:  2008-09-25       Impact factor: 38.330

  10 in total
  20 in total

Review 1.  Insulin resistance in clinical and experimental alcoholic liver disease.

Authors:  Rotonya M Carr; Jason Correnti
Journal:  Ann N Y Acad Sci       Date:  2015-05-21       Impact factor: 5.691

Review 2.  The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux.

Authors:  Varman T Samuel; Gerald I Shulman
Journal:  J Clin Invest       Date:  2016-01-04       Impact factor: 14.808

3.  Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping.

Authors:  Zhipeng Liu; Yang Zhang; Sarah Graham; Xiaokun Wang; Defeng Cai; Menghao Huang; Roger Pique-Regi; Xiaocheng Charlie Dong; Y Eugene Chen; Cristen Willer; Wanqing Liu
Journal:  J Hepatol       Date:  2020-03-10       Impact factor: 25.083

4.  In vitro cellular models of human hepatic fatty acid metabolism: differences between Huh7 and HepG2 cell lines in human and fetal bovine culturing serum.

Authors:  Pippa J Gunn; Charlotte J Green; Camilla Pramfalk; Leanne Hodson
Journal:  Physiol Rep       Date:  2017-12

5.  Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.

Authors:  Andras Franko; Susanne Neschen; Jan Rozman; Birgit Rathkolb; Michaela Aichler; Annette Feuchtinger; Laura Brachthäuser; Frauke Neff; Marketa Kovarova; Eckhard Wolf; Helmut Fuchs; Hans-Ulrich Häring; Andreas Peter; Martin Hrabě de Angelis
Journal:  Mol Metab       Date:  2017-01-06       Impact factor: 7.422

6.  Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics.

Authors:  Jingjing Jiao; Suet-Ying Kwan; Caroline M Sabotta; Honami Tanaka; Lucas Veillon; Marc O Warmoes; Philip L Lorenzi; Ying Wang; Peng Wei; Ernest T Hawk; Jose Luis Almeda; Joseph B McCormick; Susan P Fisher-Hoch; Laura Beretta
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-06-21       Impact factor: 4.254

7.  Relationship of Serum Trimethylamine N-Oxide (TMAO) Levels with early Atherosclerosis in Humans.

Authors:  Elko Randrianarisoa; Angela Lehn-Stefan; Xiaolin Wang; Miriam Hoene; Andreas Peter; Silke S Heinzmann; Xinjie Zhao; Ingmar Königsrainer; Alfred Königsrainer; Bernd Balletshofer; Jürgen Machann; Fritz Schick; Andreas Fritsche; Hans-Ulrich Häring; Guowang Xu; Rainer Lehmann; Norbert Stefan
Journal:  Sci Rep       Date:  2016-05-27       Impact factor: 4.379

Review 8.  Novel phenotypes of prediabetes?

Authors:  Hans-Ulrich Häring
Journal:  Diabetologia       Date:  2016-06-25       Impact factor: 10.122

9.  Patatin-like phospholipase domain–containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets.

Authors:  Matthew A Mitsche; Helen H Hobbs; Jonathan C Cohen
Journal:  J Biol Chem       Date:  2018-03-19       Impact factor: 5.157

Review 10.  PNPLA3 expression and its impact on the liver: current perspectives.

Authors:  Francesca Virginia Bruschi; Matteo Tardelli; Thierry Claudel; Michael Trauner
Journal:  Hepat Med       Date:  2017-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.